Evaluation of 219 Patients with Chronic Hepatitis C Receiving Pegylated Interferon

Aykin N., Cevik F. C., Naz H., Korkmaz P., US T.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.19, no.2, pp.71-75, 2013 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.4274/vhd.77486
  • Journal Name: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.71-75
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: In chronic hepatitis C (CHC) treatment, consensus guidelines recommend the use of either pegylated interferon (PEG-IFN) alfa 2a(40 KD), or PEG-IFN alfa 2b(12 KD) both plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection. The aim of this study was to evaluate treatments of CHC in our patients retrospectively.